Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Work In Process (2016 - 2018)

Historic Work In Process for Amicus Therapeutics (FOLD) over the last 3 years, with Q1 2018 value amounting to $7.2 million.

  • Amicus Therapeutics' Work In Process rose 10745.75% to $7.2 million in Q1 2018 from the same period last year, while for Mar 2018 it was $7.2 million, marking a year-over-year increase of 10745.75%. This contributed to the annual value of $3.8 million for FY2017, which is 1617.29% up from last year.
  • Per Amicus Therapeutics' latest filing, its Work In Process stood at $7.2 million for Q1 2018, which was up 10745.75% from $3.8 million recorded in Q4 2017.
  • In the past 5 years, Amicus Therapeutics' Work In Process registered a high of $7.2 million during Q1 2018, and its lowest value of $137000.0 during Q2 2016.
  • Its 3-year average for Work In Process is $4.0 million, with a median of $3.6 million in 2017.
  • The largest annual percentage gain for Amicus Therapeutics' Work In Process in the last 5 years was 264306.57% (2017), contrasted with its biggest fall of 1617.29% (2017).
  • Quarter analysis of 3 years shows Amicus Therapeutics' Work In Process stood at $3.3 million in 2016, then grew by 16.17% to $3.8 million in 2017, then surged by 87.48% to $7.2 million in 2018.
  • Its Work In Process stands at $7.2 million for Q1 2018, versus $3.8 million for Q4 2017 and $6.9 million for Q3 2017.